Ezra E Cohen

List of Publications by Year
in descending order

128 papers	12,311 citations	44444 50 h-index	31191 106 g-index
133 all docs	133 docs citations	133 times ranked	15633 citing authors

#	Article	IF	Citations
1	Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report. Journal of Otolaryngology - Head and Neck Surgery, 2022, 51, 5.	0.9	3
2	Analysis of CDK12 alterations in a panâ€cancer database. Cancer Medicine, 2022, 11, 753-763.	1.3	6
3	Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers. Cancers, 2022, 14, 33.	1.7	17
4	Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. Journal of the National Cancer Institute, 2021, 113, 171-181.	3.0	25
5	Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Modern Pathology, 2021, 34, 532-541.	2.9	63
6	The Changing Landscape of Therapeutic Cancer Vaccinesâ€”Novel Platforms and Neoantigen Identification. Clinical Cancer Research, 2021, 27, 689-703.	3.2	113
7	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy and Oncology, 2021, 156, 281-293.	0.3	157
8	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2021, 22, 450-462.	5.1	287
9	Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nature Communications, 2021, 12, 2383.	5.8	39
10	Did Everolimus Break the Rules?. Clinical Cancer Research, 2021, 27, 3807-3808.	3.2	1
11	Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncology, The, 2021, 22, 883-892.	5.1	116
12	Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clinical Cancer Research, 2021, 27, 6075-6082.	3.2	40
13	Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. Frontiers in Oncology, 2021, 11, 738626.	1.3	9
14	Inevitable Progress-Relying on the Immune System, Not Chance. Clinical Cancer Research, 2021, , clincanres.3739.2021.	3.2	0
15	Selection of Head and Neck Cancer Patients for Intensive Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 157-166.	0.4	10
16	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research, 2020, 26, 5153-5161.	3.2	58
17	Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. Journal of Clinical Oncology, 2020, 38, 2427-2437.	0.8	88
18	Tipifarnib in recurrent, metastatic HRASâ€mutant salivary gland cancer. Cancer, 2020, 126, 3972-3981.	2.0	34

#	Article	IF	Citations
19	B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. Clinical Cancer Research, 2020, 26, 3345-3359.	3.2	117
20	Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. Translational Cancer Research, 2020, 9, 203-209.	0.4	15
21	Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. Molecular Cancer Therapeutics, 2020, 19, 157-167.	1.9	21
22	Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. Journal of Medical Economics, 2020, 23, 442-447.	1.0	16
23	Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. Biomaterials, 2020, 248, 120032.	5.7	14
24	HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Cancer Research, 2020, 80, 732-746.	0.4	36
25	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
26	p16 status and choice of chemotherapy in the KEYNOTE-040 study â€“ Authors' reply. Lancet, The, 2019, 394, 1323.	6.3	0
27	Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clinical Cancer Research, 2019, 25, 4211-4223.	3.2	85
28	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Journal of Translational Medicine, 2019, 17, 429.	1.8	5
29	A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. , 2019, 7, 342.		40
30	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nature Communications, 2019, 10, 5546.	5.8	98
31	Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens. Cancer Immunology Research, 2019, 7, 40-49.	1.6	17
32	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet, The, 2019, 393, 156-167.	6.3	1,153
33	Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncology, 2018, 80, 16-22.	0.8	42
34	Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. Journal of Cancer Education, 2018, 33, 622-626.	0.6	20
35	Characterizing an Ultraâ€“High-Risk Subset of Patients With Hypopharynx and Larynx Cancer. JAMA Oncology, 2018, 4, 989.	3.4	0
36	Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. Frontiers in Oncology, 2018, 8, 435.	1.3	18

#	Article	IF	Citations
37	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 309-317.	1.1	12
38	Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer. Journal of the National Cancer Institute, 2018, 110, 1393-1399.	3.0	43
39	Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Practical Radiation Oncology, 2017, 7, 246-253.	1.1	73
40	Serum antibodies open the door to prediction and prognostication in human papillomavirusâ€“related head and neck cancer. Cancer, 2017, 123, 4310-4313.	2.0	1
41	Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Annals of Oncology, 2017, 28, 2526-2532.	0.6	70
42	Considering the survivorship care needs of head and neck cancer survivors. Oral Oncology, 2016, 57, 61-62.	0.8	0
43	American Cancer Society Head and Neck Cancer Survivorship Care Guideline. Ca-A Cancer Journal for Clinicians, 2016, 66, 203-239.	157.7	419
44	Multidisciplinary Care of Laryngeal Cancer. Journal of Oncology Practice, 2016, 12, 717-724.	2.5	35
45	PI3KÎ³ is a molecular switch that controls immune suppression. Nature, 2016, 539, 437-442.	13.7	884
46	Postoperative Management of High-Risk Resectable Head and Neck Cancer. , 2016, , 607-615.		0
47	Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nature Communications, 2016, 7, 13019.	5.8	51
48	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2016, 34, 987-1011.	0.8	141
49	Erlotinib and the Risk of Oral Cancer. JAMA Oncology, 2016, 2, 209.	3.4	111
50	A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. PLoS ONE, 2016, 11, e0152995.	1.1	17
51	The Rise of HPV-Positive Oropharyngeal Cancers in the United States. Cancer Prevention Research, 2015, 8, 9-11.	0.7	21
52	Reply to S. Chakraborty et al. Journal of Clinical Oncology, 2015, 33, 968-968.	0.8	0
53	Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncology, 2015, 51, 291-298.	0.8	136
54	Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. Cancer Letters, 2015, 359, 269-274.	3.2	9

#	Article	IF	Citations
55	Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Targeted Oncology, 2015, 10, 501-508.	1.7	22
56	Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncology, 2015, 51, 399-408.	0.8	19
57	Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clinical Cancer Research, 2015, 21, 5092-5099.	3.2	3
58	Lenvatinib in Advanced, Radioactive Iodineâ€"Refractory, Differentiated Thyroid Carcinoma. Clinical Cancer Research, 2015, 21, 5420-5426.	3.2	22
59	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2015, 33, 3305-3313.	0.8	269
60	Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 53-58.	0.8	26
61	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. Clinical Cancer Research, 2015, 21, 632-641.	3.2	525
62	p62/SQSTM1 Accumulation in Squamous Cell Carcinoma of Head and Neck Predicts Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitors. PLoS ONE, 2014, 9, e90171.	1.1	26
63	A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemotherapy and Pharmacology, 2014, 74, 1261-1270.	1.1	44
64	Efficient Cisplatin Proâ€Drug Delivery Visualized with Subâ€100 nm Resolution: Interfacing Engineered Thermosensitive Magnetomicelles with a Living System. Advanced Materials Interfaces, 2014, 1, 1400182.	1.9	22
65	Magnetomicelles: Efficient Cisplatin Proâ€Drug Delivery Visualized with Subâ€100 nm Resolution: Interfacing Engineered Thermosensitive Magnetomicelles With a Living System (Adv. Mater. Interfaces) Tj ETQq1 1 0.784314 rgBT /Ov		
66	Race and competing mortality in advanced head and neck cancer. Oral Oncology, 2014, 50, 40-44.	0.8	27
67	An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemotherapy and Pharmacology, 2014, 73, 1227-1239.	1.1	73
68	Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2014, 32, 2735-2743.	0.8	458
69	Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nature Genetics, 2014, 46, 939-943.	9.4	126
70	Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and qualityâ€ofâ€life assessments. Cancer, 2014, 120, 2694-2703.	2.0	106
71	The ACR appropriateness criteriaÂ® for thyroid carcinoma: Searching for consensus in a rapidly evolving area. Oral Oncology, 2014, 50, 575-576.	0.8	0
72	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. PLoS ONE, 2014, 9, e102112.	1.1	14

#	Article	IF	Citations
73	Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. Journal of Geriatric Oncology, 2013, 4, 327-333.	0.5	33
74	Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Molecular Oncology, 2013, 7, 359-368.	2.1	37
75	Open Access in biomedical sciences: What the current turning point means more specifically to Oral Oncology contributors and readers. Oral Oncology, 2013, 49, 985-986.	0.8	3
76	Multidisciplinary Care of the Patient with Head and Neck Cancer. Surgical Oncology Clinics of North America, 2013, 22, 179-215.	0.6	23
77	Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy. Oral Oncology, 2013, 49, 1025-1031.	0.8	16
78	Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients. Clinical Cancer Research, 2012, 18, 4785-4793.	3.2	61
79	A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2012, 18, 2336-2343.	3.2	104
80	Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research, 2012, 18, 2056-2065.	3.2	141
81	Novel targeted therapies in head and neck cancer. Expert Opinion on Investigational Drugs, 2012, 21, 281-295.	1.9	11
82	Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 2012, 48, 887-892.	0.8	42
83	Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncology, 2012, 48, 1025-1030.	0.8	13
84	Chemoradiation for patients with largeâ€volume laryngeal cancers. Head and Neck, 2012, 34, 1162-1167.	0.9	26
85	Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer, 2012, 118, 2962-2970.	2.0	295
86	Current Treatment Options for Metastatic Head and Neck Cancer. Current Treatment Options in Oncology, 2012, 13, 35-46.	1.3	197
87	Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Nonâ€“Small-Cell Lung Cancer, A Phase II Trial. Clinical Lung Cancer, 2012, 13, 123-128.	1.1	10
88	Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer. PLoS Computational Biology, 2012, 8, e1002350.	1.5	75
89	Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Translational Research, 2011, 157, 265-272.	2.2	42
90	Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244. Journal of the American Academy of Dermatology, 2011, 64, e17-e19.	0.6	8

#	Article	IF	Citations
91	Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer, 2011, 117, 4671-4678.	2.0	68
92	The Next Phase of Chemoprevention Research. Cancer Prevention Research, 2011, 4, 293-295.	0.7	0
93	Factors Associated With Long-term Speech and Swallowing Outcomes After Chemoradiotherapy for Locoregionally Advanced Head and Neck Cancer. JAMA Otolaryngology, 2010, 136, 1226.	1.5	17
94	Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2010, 28, 3336-3343.	0.8	75
95	A Genome-Wide Screen for Microdeletions Reveals Disruption of Polarity Complex Genes in Diverse Human Cancers. Cancer Research, 2010, 70, 2158-2164.	0.4	72
96	Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 358-365.	1.1	61
97	New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors. Clinical Cancer Research, 2010, 16, 2489-2495.	3.2	102
98	The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. Cancer Research, 2009, 69, 3021-3031.	0.4	236
99	A Feed-Forward Loop Involving Protein Kinase CÎ± and MicroRNAs Regulates Tumor Cell Cycle. Cancer Research, 2009, 69, 65-74.	0.4	99
100	Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2009, 27, 1864-1871.	0.8	353
101	Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head and Neck, 2009, 31, 1013-1021.	0.9	53
102	Personalizing cancer care: updates on head and neck cancer. Expert Review of Anticancer Therapy, 2009, 9, 1219-1222.	1.1	0
103	Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncology, The, 2009, 10, 247-257.	5.1	263
104	Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. Ecological Management and Restoration, 2008, 21, 514-521.	0.2	17
105	Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. Journal of Clinical Oncology, 2008, 26, 4708-4713.	0.8	593
106	Characteristics Associated With Swallowing Changes After Concurrent Chemotherapy and Radiotherapy in Patients With Head and Neck Cancer. JAMA Otolaryngology, 2008, 134, 1060.	1.5	53
107	Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Nonâ€“Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. Journal of Clinical Oncology, 2007, 25, 3978-3984.	0.8	240
108	Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors. Current Cancer Drug Targets, 2007, 7, 666-673.	0.8	19

#	Article	IF	Citations
109	A Disturbance in the Forceâ€"Mitochondrial Mutations in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2007, 13, 4317-4319.	3.2	0
110	A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer. Cancer Investigation, 2007, 25, 435-444.	0.6	10
111	Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 678-684.	0.4	38
112	A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Quality of Life Research, 2007, 16, 1615-1626.	1.5	24
113	Planned Post-Chemoradiation Neck Dissection: Significance of Radiation Dose. Laryngoscope, 2006, 116, 33-36.	1.1	61
114	Epidermal growth factor receptor directed therapy in head and neck cancer. Critical Reviews in Oncology/Hematology, 2006, 57, 25-43.	2.0	46
115	A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biology and Therapy, 2006, 5, 766-770.	1.5	106
116	Role of Epidermal Growth Factor Receptor Pathwayâ€"Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2006, 24, 2659-2665.	0.8	144
117	High Survival and Organ Function Rates After Primary Chemoradiotherapy for Intermediate-Stage Squamous Cell Carcinoma of the Head and Neck Treated in a Multicenter Phase II Trial. Journal of Clinical Oncology, 2006, 24, 3438-3444.	0.8	18
118	Protein Kinase CÎ¶ Mediates Epidermal Growth Factorâ€"Induced Growth of Head and Neck Tumor Cells by Regulating Mitogen-Activated Protein Kinase. Cancer Research, 2006, 66, 6296-6303.	0.4	70
119	Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR. Clinical Cancer Research, 2005, 11, 8105-8108.	3.2	125
120	Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2005, 11, 8418-8424.	3.2	224
121	Targeted Therapies in Head and Neck Cancer. , 2005, , 239-261.		0
122	Novel therapeutic targets in squamous cell carcinoma of the head and neck. Seminars in Oncology, 2004, 31, 755-768.	0.8	19
123	The Expanding Role of Systemic Therapy in Head and Neck Cancer. Journal of Clinical Oncology, 2004, 22, 1743-1752.	0.8	199
124	Induction chemotherapy and radiotherapy in locally advanced nonâ€"small cell lung cancer. Hematology/Oncology Clinics of North America, 2004, 18, 81-90.	0.9	6
125	Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2003, 21, 1980-1987.	0.8	568
126	An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia. Journal of Clinical Oncology, 2003, 21, 4546-4552.	0.8	135

#	Article	IF	Citations
127	Treatment of metastatic urothelial cancer in the post-MVAC era. World Journal of Urology, 2001, 19, 126-132.	1.2	3
128	Locally advanced non-small cell lung cancer. Current Treatment Options in Oncology, 2001, 2, 27-42.	1.3	0